Evidence Supports Screening for Fragile X Syndrome in Prospective Mothers
1-Jul-2010 9:00 AM EDT
Authors Stress Need for Public Education About Unfamiliar Genetic Disease
Newswise — There's adequate research data to support population screening of women of childbearing age for fragile X syndrome—the most common inherited cause of cognitive impairment, according to a report in the July issue of Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.
Given low public awareness of this very complex genetic syndrome, educational efforts and guidelines for genetic counseling will be essential. The conclusions are based on a review and analysis of previous research evidence on screening for fragile X syndrome, led by Melissa K. Hill, Ph.D., of the Murdoch Childrens Research Institute, Melbourne, Australia.
Evidence Supports Fragile X Screening in Women of Reproductive AgeFragile X syndrome, which causes cognitive impairment and other abnormalities, affects about 1 in 4,000 males in the United States (It also occurs in females, but causes less severe impairment). Fragile X syndrome is caused by relatively common mutations of a gene called FMR1. Although estimates vary, 1 in 300 to 400 U.S. couples may be carriers of the abnormal genes. In recent years, accurate and practical tests to identify carriers of the abnormal FMR1 genes have been developed.
In their review, Dr Hill and colleagues identified eleven studies evaluating the use of fragile X screening in women of reproductive age. Although some of the studies included pregnant women, there are several key advantages to identifying fragile X gene carriers before conception. The women in the studies found fragile X screening acceptable and appreciated having the option of screening, whether or not they chose to be tested.
The studies varied considerably in terms of the percentage of women who agreed to screening, as well as the rate of abnormal FMR1 gene carriers. Studies that examined the psychological issues involved in screening revealed challenging issues for genetic counseling—especially related to the lack of awareness or personal experience with fragile X syndrome in the general population.
Despite the limitations of the research, fragile X screening in women of reproductive age "clearly meets established criteria" for genetic screening programs, Dr. Hill and colleagues conclude. However, they emphasize the need for "targeted educational and counseling strategies," as well as further research to evaluate the potential impacts of fragile X screening. They write, "It is crucial that future studies offering screening for fragile X syndrome explore a range of psychosocial aspects in addition to looking at uptake of screening and mutation frequency."
More Study Needed on Newborn Screening for Fragile XIn contrast, the review found just one study evaluating the benefits of testing for fragile X syndrome in newborns—far short of the evidence needed to recommend screening. An important consideration is the fact that, unlike some other conditions for which newborn screening is performed, there's currently no early treatment that can improve the outcomes for newborns affected by fragile X syndrome.
Testing for fragile X syndrome later in infancy might be a good alternative to newborn screening, according to an accompanying editorial by Bradford Coffee, Ph.D., of Emory University. He suggests that performing fragile X screening around one year of age would allow early education for affected infants. It would also avoid the "diagnostic odyssey" experienced by families of children affected by fragile X syndrome—currently, the average age at diagnosis is about three years.
The "unique biology" of fragile X syndrome raises questions different from those of other genetic diseases, Dr. Coffee points out. Screening may detect "premutations" of the FMR1 gene that don't cause fragile X syndrome—but may cause other health problems later in life, and may lead to fragile X syndrome in future generations. In addition, many girls who test positive for the "full" FMR1 mutation don't develop fragile X syndrome.
Dr. Coffee agrees that effective public education will be an essential part of any large-scale fragile X screening program. "Given that the vast majority of the general public has never heard of fragile X syndrome, much less are aware of the complexities of screening and predictive testing of premutation-associated disorders, educational and counseling services need to be developed to inform families of the risks and benefits of the screening," Dr. Coffee writes. He adds that any type of fragile X screening program is far more likely to be successful if the process is "voluntary and transparent."
About Genetics in MedicineGenetics in Medicine is the official peer-reviewed journal of The American College of Medical Genetics. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.
About the American College of Medical GeneticsFounded in 1991, the ACMG provides education, resources and a voice for the medical genetics profession. To make genetic services available to and improve the health of the public, the ACMG promotes the development and implementation of methods to diagnose, treat and prevent genetic disease. Members include biochemical, clinical, cytogenetic, medical and molecular geneticists, genetic counselors, and other health care professionals committed to the practice of medical genetics. Genetics in Medicine, published monthly, is the official journal of the ACMG.
About Lippincott Williams & Wilkins Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services.
LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health and pharmacy. Major brands include traditional publishers of medical and drug reference tools and textbooks, such as Lippincott Williams & Wilkins and Facts & Comparisons®; and electronic information providers, such as Ovid®, UpToDate®, Medi-Span® and ProVation® Medical.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer’s leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer has 2009 annual revenues of €3.4 billion ($4.8 billion), employs approximately 19,300 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.